Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF.
Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF.
复制标题
HFpEF 人群代谢综合征与心力衰竭住院风险增加之间的关联。
DOI：
10.3389/fcvm.2021.698117
复制
发表时间：
2021
影响因子：
3.6
通讯作者：
Wang Y
中科院分区：
文献类型：
--
作者：
Zhou Y;Fu L;Sun J;Zhu Z;Xing Z;Zhou S;Tai S;Wang Y
背景资料：代谢综合征与射血分数保留性心力衰竭（HF）发生之间的关系尚未完全阐明。目的：评价代谢综合征与HFpEF患者HF住院风险之间的关系。研究方法：患者数据来自醛固酮拮抗剂治疗保留心功能心力衰竭（TOPCAT）试验数据库的美国队列。收集主要结局（因HF住院）和次要结局（全因死亡率、心血管死亡率和全因住院）的数据，应用多变量考克斯比例风险模型分析代谢综合征患者和非代谢综合征患者的风险比（HR）。结果：在1,548名参与者中，1,197人患有代谢综合征。代谢综合征患者的心功能和生活质量均低于非代谢综合征患者。在3.3年的随访期间，351例患者因HF住院。多变量校正后，HF住院和全因住院的风险（校正HR = 1.42，95% CI：1.01-2.00; p = 0.042和校正HR = 1.27; 95% CI：1.04-1.54; p = 0.017）与代谢综合征患者的HFpEF独立相关。此外，在267例倾向评分匹配的患者中，代谢综合征患者的HF住院和全因住院风险更高（分别为HR = 1.53，95% CI = 1.05-2.23，p = 0.025和HR = 1.34，95% CI = 1.08-1.67，p = 0.009）。结论：患有代谢综合征的HFpEF患者的HF住院和全因住院风险高于无代谢综合征的患者。
Background: The association between metabolic syndrome and the development of heart failure (HF) with preserved ejection fraction (HFpEF) has not been completely clarified. Aim: To evaluate the association between metabolic syndrome and the risk of HF hospitalization for patients with HFpEF. Methods: Patient data were obtained from the American cohort of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial database. Data for the primary outcome (hospitalization for HF) and secondary outcomes (all-cause mortality, cardiovascular mortality, and all-cause hospitalization) were collected, and hazard ratios (HRs) for the patients with and without metabolic syndrome were analyzed by applying a multivariable Cox proportional hazard model. Results: Among the 1,548 total participants, 1,197 had metabolic syndrome. The patients with metabolic syndrome exhibited worse heart function and a lower quality of life than those without metabolic syndrome. During the 3.3 years of follow-up, 351 patients were hospitalized for HF. After a multivariable adjustment, the risk of hospitalization for HF and all-cause hospitalization (adjusted HR = 1.42, 95% CI: 1.01–2.00; p = 0.042 and adjusted HR = 1.27; 95% CI: 1.04–1.54; p = 0.017, respectively) were independently associated with HFpEF for the patients with metabolic syndrome. In addition, the risks of HF hospitalization and all-cause hospitalization among 267 propensity score-matched patients were higher for patients with metabolic syndrome (HR = 1.53, 95% CI = 1.05–2.23, and p = 0.025 and HR = 1.34, 95% CI = 1.08–1.67, and p = 0.009, respectively). Conclusion: The risks of HF hospitalization and all-cause hospitalization were higher for patients with HFpEF having metabolic syndrome than for those without metabolic syndrome.